AMGN compared with IBRX: revenue, margins and what each company keeps, and the suppliers and customers both name

AMGNAmgen Inc

Mkt capRevenueRevenue

IBRXImmunityBio, Inc.

Mkt capRevenueRevenue

Compare

AMGNAmgen Inc

IBRXImmunityBio, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

AMGNAmgen Inc

460.67▼−1.03%· post 456.16

Mkt cap$249.4BRevenue$10.1BQ2 FY26Revenue$36.8BFY25

IBRXImmunityBio, Inc.

8.30▲+4.46%· post 8.30

ClosedNov 3 '26

Mkt cap$8.4BRevenue$51MQ2 FY26Revenue$140MFY25

Compare

ClosedNov 3 '26

AMGNAmgen Inc

IBRXImmunityBio, Inc.

460.67▼−1.03%post 456.16

Price

8.30▲+4.46%post 8.30

$249.4B

Mkt cap

$8.4B

Q2 FY26$10.1B

Revenue

$51MQ2 FY26

FY25$36.8B

Revenue

$140MFY25

AMGN460.67▼−1.03%vsIBRX8.30▲+4.46%ClosedNov 3 '26

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

IBRX: latest quarter is a loss; flow not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only AMGN 12

PODDInsuletsupplier

CYTKCytokineticssupplier

ARWRArrowhead Pharmaceuticalssupplier

LGNDLigand Pharmaceuticalssupplier

8 more · AMGN chain ›

Shared 0

No shared counterparties.

Only IBRX 3

HCWBHCW Biologicscustomer

—Accord Healthcareunlistedcustomer

—BioPharma & Cigalah Healthcareunlistedcustomer

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

Price

rebased to 0%

AMGN, solidIBRX, dashed